Skip to content

Study · Observational study · 2026

7 results

Use of Glucagon-Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009-2024.

Taipale H, Taylor M, Lähteenvuo M, Mittendorfer-Rutz E, Tanskanen A, Tiihonen J

Acta psychiatrica Scandinavica21 Jun 2026

PMID42324672 (opens in a new tab)PMCIDPMC13532777 (opens in a new tab)DOI10.1111/acps.70120 (opens in a new tab)PepBankPUB-42324672
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanObservational studyOther

    In bipolar disorder database analysis, semaglutide use was linked to lower psychiatric hospitalisation risk than non-use of GLP-1RA.

    In plain wordsDatabase analysis linked semaglutide to lower psychiatric hospitalisation risk than periods without GLP-1RA in bipolar disorder records.

    Peptide
    Semaglutide
    Outcome
    DecreasePsychiatric hospitalisation
    Study

    n: not reported in source

    Comparator
    non-use of GLP-1RA in the same individual
    Analysis
    Primary
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Measurements

    Adjusted hazard ratio
    0.79 aHR
    semaglutide versus non-use, psychiatric hospitalisation
    95% CI of aHR
    0.69 to 0.91 aHR
    semaglutide versus non-use, psychiatric hospitalisation
    Risk reduction
    21%
    semaglutide versus non-use, psychiatric hospitalisation

    Source sentences

    Summary
    Semaglutide was associated with a 21% (aHR 0.79, 95% CI 0.69-0.91) lower risk of psychiatric hospitalisation compared with non-use of GLP-1RA in that same individual.
    3 context sentences
    Summary · context
    The study cohort was derived from the National Swedish Registers and included all people with a diagnosis of bipolar disorder who used any antidiabetic medication, between the years 2009 and 2024.
    Summary · context
    GLP-1RA individually and as a group were compared with non-use of GLP-1RA, and directly with other second-line antidiabetic medications.
    Summary · context
    A within-individual design was utilised for all comparisons to reduce confounding.
  2. 02HumanObservational studyOther

    In bipolar disorder database analysis, liraglutide was not specifically linked to lower psychiatric hospitalisation risk than non-use of GLP-1RA.

    In plain wordsDatabase analysis did not link liraglutide to lower psychiatric hospitalisation risk than periods without GLP-1RA.

    Peptide
    Liraglutide
    Outcome
    No significant changePsychiatric hospitalisation
    Study

    n: not reported in source

    Comparator
    non-use of GLP-1RA in the same individual
    Analysis
    Primary
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide and dulaglutide were not specifically associated with a lower hospitalisation risk.
    3 context sentences
    Summary · context
    The study cohort was derived from the National Swedish Registers and included all people with a diagnosis of bipolar disorder who used any antidiabetic medication, between the years 2009 and 2024.
    Summary · context
    GLP-1RA individually and as a group were compared with non-use of GLP-1RA, and directly with other second-line antidiabetic medications.
    Summary · context
    A within-individual design was utilised for all comparisons to reduce confounding.
  3. 03HumanObservational studyOther

    In bipolar disorder database analysis, dulaglutide was not specifically linked to lower psychiatric hospitalisation risk than non-use of GLP-1RA.

    In plain wordsDatabase analysis did not link dulaglutide to lower psychiatric hospitalisation risk than periods without GLP-1RA.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Direction not reportedPsychiatric hospitalisation
    Study

    Homo sapiensn: not reported in source

    People with bipolar disorder using antidiabetic medication in the National Swedish Registers
    Comparator
    non-use of GLP-1RA in the same individual
    Analysis
    Primary
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide and dulaglutide were not specifically associated with a lower hospitalisation risk.
    3 context sentences
    Summary · context
    The study cohort was derived from the National Swedish Registers and included all people with a diagnosis of bipolar disorder who used any antidiabetic medication, between the years 2009 and 2024.
    Summary · context
    GLP-1RA individually and as a group were compared with non-use of GLP-1RA, and directly with other second-line antidiabetic medications.
    Summary · context
    A within-individual design was utilised for all comparisons to reduce confounding.
  4. 04HumanObservational studyOther

    In people with bipolar disorder in Swedish registers, semaglutide use was linked to a lower risk of bipolar disorder relapse than periods without GLP-1RA use.

    In plain wordsRegister data linked semaglutide to a lower risk of bipolar relapse than periods in the same person without GLP-1RA.

    Peptide
    Semaglutide
    Outcome
    DecreaseBipolar disorder relapse
    Study

    n: not reported in source

    Comparator
    non-use of GLP-1RA in the same individual
    Analysis
    Secondary
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Measurements

    Adjusted hazard ratio
    0.83 aHR
    semaglutide versus non-use, relapse
    95% CI of aHR
    0.69 to 0.99 aHR
    semaglutide versus non-use, relapse
    Risk reduction
    17%
    semaglutide versus non-use, relapse

    Source sentences

    Summary
    Semaglutide was also linked to a 17% (aHR 0.83, 95% CI 0.69-0.99) lower risk of relapse of bipolar disorder.
    3 context sentences
    Summary · context
    The study cohort was derived from the National Swedish Registers and included all people with a diagnosis of bipolar disorder who used any antidiabetic medication, between the years 2009 and 2024.
    Summary · context
    GLP-1RA individually and as a group were compared with non-use of GLP-1RA, and directly with other second-line antidiabetic medications.
    Summary · context
    A within-individual design was utilised for all comparisons to reduce confounding.
  5. 05HumanObservational studyOther

    In bipolar disorder database analysis, semaglutide was not significantly linked to psychiatric sick leave.

    In plain wordsDatabase analysis found no significant psychiatric sick leave difference with semaglutide versus periods without GLP-1RA.

    Peptide
    Semaglutide
    Outcome
    No significant changePsychiatric sick leave
    Study

    n: not reported in source

    Comparator
    non-use of GLP-1RA in the same individual
    Analysis
    Secondary
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Absences from work due to sick leave were not significantly associated with the specific antidiabetic medications studied.
    3 context sentences
    Summary · context
    The study cohort was derived from the National Swedish Registers and included all people with a diagnosis of bipolar disorder who used any antidiabetic medication, between the years 2009 and 2024.
    Summary · context
    GLP-1RA individually and as a group were compared with non-use of GLP-1RA, and directly with other second-line antidiabetic medications.
    Summary · context
    A within-individual design was utilised for all comparisons to reduce confounding.
  6. 06HumanObservational studyOther

    In bipolar disorder database analysis, liraglutide was not significantly linked to psychiatric sick leave.

    In plain wordsDatabase analysis found no significant psychiatric sick leave difference with liraglutide versus periods without GLP-1RA.

    Peptide
    Liraglutide
    Outcome
    No significant changePsychiatric sick leave
    Study

    n: not reported in source

    Comparator
    non-use of GLP-1RA in the same individual
    Analysis
    Secondary
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Absences from work due to sick leave were not significantly associated with the specific antidiabetic medications studied.
    3 context sentences
    Summary · context
    The study cohort was derived from the National Swedish Registers and included all people with a diagnosis of bipolar disorder who used any antidiabetic medication, between the years 2009 and 2024.
    Summary · context
    GLP-1RA individually and as a group were compared with non-use of GLP-1RA, and directly with other second-line antidiabetic medications.
    Summary · context
    A within-individual design was utilised for all comparisons to reduce confounding.
  7. 07HumanObservational studyOther

    In bipolar disorder database analysis, dulaglutide was not significantly linked to psychiatric sick leave.

    In plain wordsDatabase analysis found no significant psychiatric sick leave difference with dulaglutide versus periods without GLP-1RA.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changePsychiatric sick leave
    Study

    Homo sapiensn: not reported in source

    People with bipolar disorder using antidiabetic medication in the National Swedish Registers
    Comparator
    non-use of GLP-1RA in the same individual
    Analysis
    Secondary
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Absences from work due to sick leave were not significantly associated with the specific antidiabetic medications studied.
    3 context sentences
    Summary · context
    The study cohort was derived from the National Swedish Registers and included all people with a diagnosis of bipolar disorder who used any antidiabetic medication, between the years 2009 and 2024.
    Summary · context
    GLP-1RA individually and as a group were compared with non-use of GLP-1RA, and directly with other second-line antidiabetic medications.
    Summary · context
    A within-individual design was utilised for all comparisons to reduce confounding.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Versions 2 to 3

    21 Oct 2026, 18:59 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.